TY - JOUR
T1 - Evolving therapies for the treatment of viral hepatitis
AU - Poordad, F. F.
AU - Gish, R. G.
PY - 1999/1/1
Y1 - 1999/1/1
N2 - Viral hepatitis refers to a spectrum of diseases caused by one of eight identified hepatotropic viruses that affect humans. The most important, in terms of morbidity and cost to healthcare systems, are hepatitis B and C, which collectively affect over 500 m people worldwide. Causes of morbidity and mortality relate to cirrhosis, disability, portal hypertension and its complications, as well as hepatocellular carcinoma, one of the most common somatic malignancies worldwide. Historically, interferon (IFN) has been the only treatment available to treat chronic viral hepatitis, but there are several other potentially effective alternatives on the horizon.
AB - Viral hepatitis refers to a spectrum of diseases caused by one of eight identified hepatotropic viruses that affect humans. The most important, in terms of morbidity and cost to healthcare systems, are hepatitis B and C, which collectively affect over 500 m people worldwide. Causes of morbidity and mortality relate to cirrhosis, disability, portal hypertension and its complications, as well as hepatocellular carcinoma, one of the most common somatic malignancies worldwide. Historically, interferon (IFN) has been the only treatment available to treat chronic viral hepatitis, but there are several other potentially effective alternatives on the horizon.
UR - http://www.scopus.com/inward/record.url?scp=0032908321&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0032908321&partnerID=8YFLogxK
U2 - 10.1517/14728214.4.1.15
DO - 10.1517/14728214.4.1.15
M3 - Review article
AN - SCOPUS:0032908321
SN - 1472-8214
VL - 4
SP - 15
EP - 34
JO - Expert Opinion on Emerging Drugs
JF - Expert Opinion on Emerging Drugs
ER -